Contract Pharmaceutical Manufacturing, Research and Packaging

Published - Oct 2009| Analyst - Shalini Shahani Dewan| Code - PHM043C
Market Research Report Single User License: $2750 Member Price: FREE

Report Highlights

  • Overall sales in the pharmaceutical contract manufacturing and contract research market were worth nearly $143 billion in 2007, which increased to an estimated $177 billion in 2009. By 2014, sales are projected to increase to nearly $299 billion, for a 5-year CAGR of 11.1%.
  • The largest segment in the market, contract manufacture of OTC and nutraceuticals, was valued at $82 billion in 2007. This increased to an estimated $103 billion in 2009, and is projected to reach $177 billion in 2014, for a 5-year CAGR of 11.4%.
  • Sales in the contract manufacture of bulk- and dosage-form drugs segment were worth $36 billion in 2007, and were to increase to nearly $44 billion in 2009. By 2014, they are projected to increase to $73 billion, for a 5-year CAGR of 10.8%..


BCC’s goal in conducting this study is to provide an overview of the current and future characteristics of the global market for contract manufacturing, research, and packaging in the pharmaceuticals industry. The key objective is to present a comprehensive analysis of the current market and its future direction in the pharmaceuticals and biotechnology outsourcing industry with the emphasis on contract manufacturing.
This report explores present and future strategies within the contract manufacturing, research, and packaging pharmaceuticals industry. The needs, services offered, criteria for selection, and the advantages of outsourcing are discussed. The study also includes the need for project management, market forecasts and a discussion of the market leaders in the industry. Regulatory requirements and current state of the outsourcing market in the pharmaceuticals and biotechnology industry are also portrayed in this report.
A detailed analysis of the pharmaceutical-biopharmaceutical contract manufacturing, research, and packaging industry structure has been conducted. Revenues are broken down by bulk as well as by dosage forms of solid, liquid, and semisolid pharmaceuticals. Sales figures are estimated for the 5 year period from 2009 through 2014.
Over-the-counter (OTC), nutritional, and drug-delivery products are discussed separately in this report. Contract research and contract packaging are also discussed separately
Many pharmaceutical companies choose outsourcing as an option, or choice, to better market their products without spending time in drug discovery and the manufacturing process. These pharmaceutical companies rely on contract manufacturers and researchers. This study examines the different types of contracting companies in the pharmaceuticals industry. Rapid development of technologies and major changes in market behavior also justify a focus on this segment.
Several important trends in outsourcing need to be tracked and analyzed. Outsourcing in the pharmaceuticals industry has changed in recent years. The major reason behind the use of contract-manufacturing organizations (CMOs) in the pharmaceuticals industry is the innovative and state-of-the-art process and production technologies CMOs offer. Other reasons to contract an outsourced company are to achieve efficiencies in cost, capacity, time-to-market, and the need to obtain specific expertise not available in-house.
This study contributes to the areas of market growth in pharmaceuticals contract manufacturing, research, and packaging from the point of view of manufacturers and users. Biochemical companies, physicians, the pharmaceuticals and biopharmaceuticals industries, and pharmaceutical research companies will find value in this study. 
The scope of this study encompasses the contract manufacturing, research, and packaging markets. BCC analyzes each market and its applications by its need for outsourcing, regulatory environment, technology involved, market projections, and market share. Technological issues include the latest trends and developments.
BCC conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with various analytical, chemical, pharmaceutical, and contracting experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.
Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of pharmaceuticals through contract manufacturing and research. Data were gathered from various industry sources. BCC spoke with officials and physicians within the industry, and consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade, and government sources.
Shalini S. Dewan holds a master’s degree in pharmaceutical chemistry. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest, from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are Reagents of Chromatography; Spectroscopy, an Enduring Market; Advanced Drug Delivery Systems; Orthopedic Drugs, Implants and Devices; Imaging Reagents; Regulatory Industry; and Dynamic Sera, Media and Reagents Used in Biotechnology.
BCC offers an online information retrieval service. BCC’s home page, located at, enables readers to:
  • Examine BCC’s complete catalog of Market Research Reports and place direct orders
  • Subscribe to any of BCC’s many industry newsletters
  • Read announcements of recently published reports and newly launched newsletters
  • Register for BCC’s well-known conferences
  • Request additional information on any BCC product
  • Take advantage of special offers
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at
Note: Reports are discounted or included with certain Memberships. See Membership Options.
Published - Aug-2007| Analyst - Shalini Shahani Dewan| Code - PHM043B

Report Highlights

  • Worldwide revenue for contract manufacture of prescription drugs (dosage forms) for 2004 was $11.1 billion, which is projected to increase at a compound annual growth rate (CAGR) of 9.4%, reaching $22.5 billion by the end of 2011.
  • Contract manufacture of over-the-counter and nutritional products worldwide is projected to reach $108.8 billion by 2011 increasing at a CAGR of 8.1%. Contract research revenues are projected to reach $24.3 billion by 2011, increasing from $17.3 billion in 2006 at a CAGR of 7.0%.
  • Contract manufacturing in the bulk drug market had worldwide revenue of about $13.5 billion in 2004.
Published - May-2005| Analyst - Shalini Shahani Dewan| Code - PHM043A

Report Highlights

  • Worldwide revenue for contract manufacturing and research for the pharmaceutical industry was estimated at $100 billion in 2004 and is expected to rise at an average annual growth rate (AAGR) of 10.8% to $168 billion in 2009.
  • Contract manufacturing of prescription drugs for 2004 was estimated at $26.2 billion, and is expected to rise to $43.9 billion by end of 2009.
  • Contract manufacturing of OTC and nutritional products is the largest and fastest growing segment, expected to rise at an AAGR of 11.3% to $102 billion by 2009.
  • The contract research market is expected to reach $21.9 billion by 2009, rising at an AAGR of 8.6% from $ 14.5 billion in 2004.

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report